{"id":"NCT02607735","sponsor":"Gilead Sciences","briefTitle":"Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy","officialTitle":"A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects With Chronic HCV Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-11","primaryCompletion":"2016-10-10","completion":"2017-06-21","firstPosted":"2015-11-18","resultsPosted":"2017-12-13","lastUpdate":"2019-03-05"},"enrollment":416,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"SOF/VEL/VOX","otherNames":["VoseviÂ®","GS-7977/GS-5816/GS-9857"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SOF/VEL/VOX (Primary Study)","type":"EXPERIMENTAL"},{"label":"Placebo (Primary Study)","type":"EXPERIMENTAL"},{"label":"SOF/VEL/VOX (Deferred Treatment Substudy)","type":"EXPERIMENTAL"}],"summary":"The primary objectives of this study are to evaluate the safety and efficacy of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in adults with chronic hepatitis C virus (HCV) infection who have previously received treatment with direct-acting antiviral therapy.\n\nParticipants randomized to placebo may be eligible for deferred treatment with active SOF/VEL/VOX.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) (Primary Study)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF/VEL/VOX (Primary Study)","deltaMin":96.2,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":86,"countries":["United States","Australia","Canada","France","Germany","New Zealand","Puerto Rico","United Kingdom"]},"refs":{"pmids":["29155352","29859740","28564569"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":263},"commonTop":["Headache","Fatigue","Diarrhoea","Nausea","Asthenia"]}}